Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma

European Urology

Volumn 71, Issue 5, 2017, Pages 719-722

  Bex, Axel ^a   Albiges, Laurence ^b   Ljungberg, Börje ^c   Bensalah, Karim ^d   Dabestani, Saeed ^e   Giles, Rachel H ^f,g   Hofmann, Fabian ^h   Hora, Milan ⁱ   Kuczyk, Markus A ^j   Lam, Thomas B ^k,l   Marconi, Lorenzo ^m   Merseburger, Axel S ⁿ   Staehler, Michael ^o   Volpe, Alessandro ^p   Powles, Thomas ^q  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UMEÅ UNIVERSITY   (Sweden)

^d UNIVERSITÉ DE RENNES 1   (France)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f International Kidney Cancer Coalition   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h SUNDERBY HOSPITAL   (Sweden)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^l UNIVERSITY OF ABERDEEN   (United Kingdom)

^m CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^p MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^q QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

Adjuvant; Guidelines; Management; Renal cell cancer; Sorafenib; Sunitinib

Indexed keywords

PLACEBO; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; COST EFFECTIVENESS ANALYSIS; EUROPEAN; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; NEPHRECTOMY; PATIENT ADVOCACY; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT DURATION; UROLOGY; ADJUVANT CHEMOTHERAPY; EUROPE; MEDICAL SOCIETY; PATHOLOGY; RENAL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; EUROPE; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEPHRECTOMY; PRACTICE GUIDELINES AS TOPIC; PYRROLES; SOCIETIES, MEDICAL; UROLOGY;

EID: 85008208816     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.11.034     Document Type: Article

References (10)

1. [1] Ljungberg, B., Bensalah, K., Canfield, S., et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67 (2015), 913–924.
2. [2] Buchler, T., Bortlicek, Z., Poprach, A., et al. Outcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysis. Eur Urol 70 (2016), 469–475.
3. [3] Ravaud, A., Motzer, R.J., Pandha, H.S., et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375 (2016), 2246–2254.
4. [4] Haas, N.B., Manola, J., Uzzo, R.G., et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387 (2016), 2008–2016.
5. [5] Coleman, R., Powles, T., Paterson, A., et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386 (2015), 1353–1361.
6. [6] Wheler, J., Johnson, M., Seidman, A., Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. Semin Oncol 33 (2006), 672–680.
7. [7] Dowsett, M., Forbes, J.F., Bradley, R., et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386 (2015), 1341–1352.
8. [8] Ko, J.J., Xie, W., Kroeger, N., et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 16 (2015), 293–300.
9. [9] Powles, T., Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns. Clin Genitourin Cancer 10 (2012), 67–68.
10. [10] Petersen, S.H., Harling, H., Kirkeby, L.T., Wille-Jorgensen, P., Mocellin, S., Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev, 2012, 2012, CD004078.